Blocklisting Six Monthly Return
London: Monday, June 29, 2020: Hutchison China MediTech Limited ("Chi-Med" or the "Company") (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return:
| 1. |
Name of applicant:
|
|
Hutchison China MediTech Limited |
|
| 2. |
Name of scheme:
|
|
(a) |
Share Option Scheme conditionally adopted by Hutchison China MediTech Limited in 2005 ("2005 HCML Share Option Scheme")
|
| |
|
(b) |
Share Option Scheme conditionally adopted by Hutchison China MediTech Limited in 2015 ("2015 HCML Share Option Scheme")
|
|
| 3. |
Period of return:
|
|
From December 29, 2019 to June 28, 2020
|
|
| 4. |
Balance under scheme from previous return:
|
|
(a) |
2005 HCML Share Option Scheme: 1,738,910 ordinary shares of US$0.1 each
|
| |
(b) |
2015 HCML Share Option Scheme: 23,130,970 ordinary shares of US$0.1 each
|
||
| 5. |
The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return:
|
|
(a) |
2005 HCML Share Option Scheme: Nil
|
| |
|
(b) |
2015 HCML Share Option Scheme: Nil
|
|
| 6. |
Number of securities issued/allotted under scheme during period:
|
|
(a) |
2005 HCML Share Option Scheme: Nil
|
| |
|
(b) |
2015 HCML Share Option Scheme: Nil
|
|
| 7. |
Balance under scheme not yet issued/allotted at end of the period:
|
|
(a) |
2005 HCML Share Option Scheme: 1,738,910 ordinary shares of US$0.1 each
|
| |
|
(b) |
2015 HCML Share Option Scheme: 23,130,970 ordinary shares of US$0.1 each
|
|
| 8. |
Number and class of securities originally listed and the date of admission:
|
|
25,198,880 ordinary shares of US$0.1 each admitted on June 17, 2019 (to replace the Company's previous block admission schemes following the Company's share subdivision which took effect on May 30, 2019) |
|
| |
|
|||
| |
|
|||
| |
|
|||
| |
|
|
|
|
| 9. |
Total number of securities in issue at the end of the period:
|
|
690,574,765 ordinary shares of US$0.1 each |
|
| Name of contact:
|
|
Christian Hogg |
||
| Address of contact:
|
|
Level 18, The Metropolis Tower, 10 Metropolis Drive, Hung Hom, Kowloon, Hong Kong
|
||
| Telephone number of contact: |
|
+852 2121 8200 |
||
About Chi-Med
Chi-Med (Nasdaq/AIM: HCM) is an innovative biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com.
CONTACTS
| Investor Enquiries |
|
| Mark Lee, Senior Vice President |
+852 2121 8200 |
| Annie Cheng, Vice President |
+1 (973) 567 3786 |
| |
|
| Media Enquiries |
|
| Americas - Brad Miles, Solebury Trout |
+1 (917) 570 7340 (Mobile) |
| Europe - Ben Atwell / Alex Shaw, FTI Consulting |
+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) |
| Asia - Joseph Chi Lo / Zhou Yi, Brunswick |
+852 9850 5033 (Mobile), [email protected] / +852 9783 6894 (Mobile), y[email protected] |
| |
|
| Nominated Advisor |
|
| Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) Limited |
+44 (20) 7886 2500 |